DATROWAY, a TROP2-directed antibody drug conjugate (ADC), has been approved in the European Union for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have received endocrine therapy and at least one line of chemotherapy.
AbbVie's Elahere achieved a 51.9% objective response rate (ORR) in heavily pre-treated patients with FRα-positive platinum-sensitive ovarian cancer (PSOC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.